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T cell surveillance is often effective against virus-associated tumors because of their high immunogenicity. It 
is not clear why surveillance occasionally fails, particularly against hepatitis B virus– or hepatitis C virus–asso-
ciated hepatocellular carcinoma (HCC). We established a transgenic murine model of virus-induced HCC by 
hepatocyte-specific adenovirus-induced activation of the oncogenic SV40 large T antigen (TAg). Adenovirus 
infection induced cytotoxic T lymphocytes (CTLs) targeted against the virus and TAg, leading to clearance of 
the infected cells. Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped 
immune clearance and progressed to HCC. These cells expressed TAg at levels similar to HCC isolated from 
neonatal TAg-tolerant mice, suggesting that CTL clearance does not select for cells with low immunogenicity. 
Virus-infected mice revealed significantly greater T cell infiltration in early-stage HCC compared with that in 
late-stage HCC, demonstrating progressive local immune suppression through inefficient T cell infiltration. 
Programmed cell death protein-1 (PD-1) and its ligand PD-L1 were expressed in all TAg-specific CD8+ T cells 
and HCC, respectively, which contributed to local tumor-antigen-specific tolerance. Thus, we have developed 
a model of virus-induced HCC that may allow for a better understanding of human HCC.
Introduction
T cell surveillance is often effective against virus-induced tumors 
because of their high immunogenicity (1, 2). It remains unclear why 
surveillance occasionally fails, e.g., against hepatitis B virus–associ-
ated (HBV-associated) or hepatitis C virus–associated (HCV-asso-
ciated) hepatocellular carcinoma (HCC). Possible reasons could be 
an initial failure to induce effective T cells (3–5), T cell exhaustion 
due to chronic antigen stimulation (6, 7), tumor-induced toler-
ance (8), immune escape by loss of immunogenicity (9), or tumor 
development in tolerogenic organs, e.g., the liver (10). In humans, 
T cell responses appear to be more efficient in those individuals 
who completely cleared the virus (11, 12); however, it is difficult 
to identify individuals in the acute infection phase (4, 12). HCC 
progresses in a great proportion of individuals with chronic HCV 
infection in the presence of virus-specific CD8+ T cells (13–15). On 
the other hand, impaired HCV-specific T cell responses have been 
observed in PBMCs or liver biopsies obtained from patients with 
chronic HCV infection (4, 16–18). Heterogeneity within individ-
uals, difficulties in analyzing local T cell responses, and the need 
of in vitro manipulation and expansion for functional analysis of 
HCV-specific T cells make firm conclusions difficult. Likewise, in 
chimpanzees, no strict correlation between virus clearance and vig-
orous T cell responses was observed (19, 20).
Several HCV transgenic mouse lines with constitutive or 
inducible HCV expression and models that allow infection of 
hepatocytes by HCV have been generated (21–28). While these 
models have yielded important information about viral patho-
genesis, the mice were either tolerant for viral antigens or did not 
develop HCC with reliable, high frequency. Thus, the endogenous 
T cell response to virus-induced HCC throughout the course of the 
disease has not been analyzed. To overcome the problem of T cell 
tolerance to viral antigens, T cells from HBV-immunized wild-type 
mice were transferred into HBV transgenic mice. The data showed 
that CD8+ T cells were mainly responsible for hepatitis and that 
viral replication was abolished by cytolytic and noncytolytic mech-
anisms (29). The chronic necroinflammatory T cell response was 
suggested to contribute to HCC development (30). On the other 
hand, HCC developed in some HCV transgenic mice independent 
of inflammation (25), and it is not clear whether the fate of adop-
tively transferred CD8+ T cells recapitulates that of the endoge-
nous T cell pool following viral infection. Here, we established 
a model of virus-induced HCC, in which a viral oncogene, SV40 
large T antigen (TAg), was activated in hepatocytes through viral 
infection of a host, LoxP-TAg mice, that can efficiently respond to 
TAg. In LoxP-TAg mice, Cre recombinase–encoding adenoviruses 
(Ad.Cre) with high tropism for the liver deleted a stop cassette, 
which prevented TAg expression. Previously, we have shown that 
these mice have retained CD8+ T cells against peptide IV (pIV), the 
dominant epitope of TAg, which could be induced by prophylactic 
immunization for protection from sporadic tumors that occur late 
in life (8, 31). In contrast to mice with virus-induced HCC reported 
here, mice with sporadic lesions readily developed TAg-specific 
CD8+ T cell tolerance.
Results
Virus-induced oncogene activation and HCC development. LoxP-TAg mice 
allow activation of the dormant TAg oncogene by Cre/loxP recombi-
nase–mediated stop cassette deletion (Figure 1A). Based on Ad.Cre 
infection of the liver we established a model for virus-induced HCC. 
LoxP-TAg mice were injected i.v. with Ad.Cre and monitored for 
tumor development by MRI, palpation, and determination of liver 
enzymes alanine aminotransferase (ALT) and aspartate transami-
nase (AST). By MRI, tumors of around 2.5 × 2.5 mm in size were 
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detected in the liver 8–16 weeks after virus infection (Figure 1B). 
Elevated ALT and AST levels were detected 1 week after virus 
infection, indicating liver damage (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI64742DS1). After 4 to 6 weeks, ALT/AST values returned to 
slightly elevated levels, when compared with those of control mice, 
and subsequently increased proportionally to HCC development. 
The virus-induced TAg activation induced multinodular HCC of 
classical type, resembling hepatocytes with a predominantly trabec-
ular (plate-like) architectural pattern within 8 to 24 weeks (in some 
Figure 1
LoxP-TAg transgenic mice develop HCC after i.v. injection of Ad.Cre. (A) Cre recombinase–mediated TAg activation. (B) For induction of HCC, 
8- to 12-week-old LoxP-TAg mice were injected i.v. with 1 × 109 PFUs of Ad.Cre, and HCC development was detected by MRI and palpation. 
Representative MR images (left) and macroscopically visible tumors of livers 10 (middle) and 20 weeks (right) after Ad.Cre injection are shown. 
MR image and liver photograph (middle) are from the same mouse. Arrows indicate tumor nodules. (C) LoxP-TAg mice that received Ad.Cre (red 
line, n = 14) and double-transgenic LoxP-TAg × Alb-Cre (DTg) mice (blue line, n = 15) were monitored for HCC development. Nontreated LoxP-TAg 
mice (black line; n = 10) served as control. Time after adenovirus injection is given for Ad.Cre-injected mice, and age is given for double-transgenic 
LoxP-TAg × Alb-Cre mice. (D) Immunohistology of liver tissue sections of LoxP-TAg mice at different time points after Ad.Cre injection as indicated. 
Tissues were stained with antibodies specific for TAg and Ki-67 and counterstained with hematoxylin. Scale bar: 100 μm. At least 3 mice were 
analyzed for each time point, and a representative staining is shown. Schematic drawings show an overview of the cumulative data of the average 
tumor number and progression not considering inter-mouse variability.
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mice 35 weeks) (Figure 1, C and D, and Supplemental Figure 2). 
In comparison, neonatal TAg-tolerant LoxP-TAg × albumin-Cre 
(Alb-Cre) mice that express the Cre recombinase by the albumin 
promoter and activate TAg in the liver early in life developed HCC 
within 7 to 14 weeks of age (Figure 1C). Upon liver tumor devel-
opment, LoxP-TAg × Alb-Cre mice showed an increase of ALT/
AST values that stayed elevated until mice succumbed to HCC and 
cholangiolar carcinoma (Supplemental Figure 3). Nontreated LoxP- 
TAg mice did not develop HCC or pathological abnormalities 
in the liver during the more than 12-month observation time, as 
assessed by MRI, histology (data not shown), and determination of 
liver enzymes ALT and AST (Supplemental Figure 4). TAg expres-
sion was abundantly detected throughout the liver 1 week after 
viral infection (Figure 1D). Ki-67 expression often mirrored TAg 
expression, indicating abundant cell proliferation in TAg-express-
ing hepatocytes. Within the next 3 weeks, TAg+ cells were almost 
completely eliminated, leaving behind few microscopically small 
TAg+ lesions, which then progressed to HCC (Figure 1D).
TAg recognition during viral infection induces T cell immunity. Our 
model is based on the assumption that the stop cassette is deleted 
and TAg is activated in virus-infected liver cells and that TAg is rec-
ognized by the adaptive immune system concomitant with a strong 
antiadenoviral immune response. Within 3 weeks after Ad.Cre 
infection, LoxP-TAg mice developed high anti-TAg IgG antibody 
titers, demonstrating that TAg was rapidly recognized by the adap-
tive immune system and suggesting functional CD4+ T cell activa-
tion (Figure 2A). Neither Ad.Cre infection of C57BL/6 (B6) mice 
nor luciferase-encoding adenovirus (Ad.Luc) infection of LoxP-TAg 
mice induced anti-TAg antibodies. Bioluminescence (BL) imaging 
of Ad.Luc-infected LoxP-TAg mice confirmed the high tropism for 
the liver (Supplemental Figure 5). The TAg-specific IgG antibod-
ies were of IgG1, IgG2a, and IgG2b isotypes (Figure 2B). Because 
Figure 2
Immunity to the cancer-driving oncogene following virus-induced activation. (A) The amount of TAg-specific IgG antibodies was determined in 
serum obtained from B6 (n = 4) and LoxP-TAg mice (Tg) 3 (n = 14) and 20 weeks (n = 7) after i.v. injection of Ad.Cre (1 × 109 PFUs). Bars indicate 
mean values. As controls, LoxP-TAg mice were i.v. injected with 1 × 109 PFUs of Ad.Luc (n = 4). LoxP-TAg mice analyzed 20 weeks after Ad.Cre 
injection had macroscopically visible tumors (see Figure 1, B and D). (B) LoxP-TAg mice develop TAg-specific antibodies of IgG1, IgG2a, and 
IgG2b isotypes upon Ad.Cre-mediated TAg activation. Amounts of TAg-specific IgG1, IgG2a, IgG2b, and IgG3 were determined in serum obtained 
from individual mice 3 and 20 weeks after Ad.Cre application. IgG3 was not detectable in any serum sample (not shown). Each number represents 
an individual mouse. LTB, large tumor bearing. (C) CD4+ T cell–deficient (Cd4–/– × LoxP-TAg; n = 6) and CD8+ T cell–deficient mice (Cd8–/– × LoxP- 
TAg; n = 4) received 1 × 109 PFUs of Ad.Cre and were monitored for HCC development. Ad.Cre-treated T cell–competent LoxP-TAg mice (WT × 
LoxP-TAg; n = 5) served as controls. (D) Ad.Cre-treated Rag2–/–cg–/– × LoxP-TAg mice (n = 7) were monitored for HCC development. LoxP-TAg 
mice (n = 6) served as control. (E) TAg-tolerant Vil-Cre × LoxP-TAg mice (n = 6) were injected with 1 × 109 PFUs of Ad.Cre and monitored for HCC 
development. LoxP-TAg mice (n = 9) served as controls. (C–E) Time after adenovirus infection is given.
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the IgG1 isotype was not observed in LoxP-TAg mice with sporadic 
tumors, TAg recognition in the viral context apparently induced 
functionally different CD4+ T cells. During subsequent HCC pro-
gression, anti-TAg IgG serum titers increased to dramatically high 
levels (Figure 2A). In order to directly assess the role of T cells dur-
ing HCC development, CD4+ and CD8+ T cell–deficient LoxP-TAg 
mice were infected with Ad.Cre. The absence of both CD4+ T cells 
and CD8+ T cells substantially reduced the latency of virus-induced 
HCC in comparison with that in T cell competent–LoxP- 
TAg littermates (Figure 2C). Similarly, strongly acceler-
ated HCC development was observed in combined Rag-2/
IL-2 receptor γ chain–deficient LoxP-TAg mice, which lack 
T cells, B cells, and NK cells (Figure 2D). Because the 
immune deficiency also might have abolished antiadeno-
viral T cell responses and clearance of virus-infected cells, 
HCCs were induced by viral infection in villin-Cre (Vil-Cre) 
× LoxP-TAg double-transgenic mice. Due to constitutive 
stop cassette deletion and TAg activation in epithelial cells 
of the gastrointestinal tract, these mice had developed neo-
natal cytotoxic T lymphocyte (CTL) tolerance for TAg but 
were otherwise immune competent (32). Virus-induced 
HCC developed with similar reduced latency in Vil-Cre × 
LoxP-TAg mice as in T cell–deficient mice (Figure 2E). Col-
lectively, the data indicate that virus-induced TAg activation 
in hepatocytes led to T cell immunity, which inhibited but 
did not prevent HCC development long term. Furthermore, 
TAg-specific T cells were mainly responsible for impairing 
HCC progression.
Virus-induced HCCs “sneak through” despite persistently functional 
CTLs. In LoxP-TAg mice with sporadic tumors, anti-TAg IgG anti-
bodies predicted TAg-specific CTL tolerance (31). In contrast, in 
vivo CTL assays in Ad.Cre-infected LoxP-TAg mice revealed that 
functional CTLs directed against the immunodominant TAg pIV 
were induced as early as 2 weeks after virus infection (Figure 3, A 
and B). Remarkably, pIV-specific CTLs persisted in the presence of 
progressing TAg+ HCC (Figure 3B). The strongest pIV-specific CTL 
Figure 3
Ad.Cre-mediated TAg activation in LoxP-TAg mice induces 
functional pIV-specific CTLs, which increase with tumor bur-
den. CTL activity against pIV alone or simultaneously against 
pIV and adenovirus dbp43 was analyzed in vivo. For simulta-
neous detection of CTL activity against pIV and dbp43, non-
loaded and pIV- and dbp43-loaded CD45.1 congenic spleen 
cells (1 × 107 each) were labeled with different amounts of 
CFSE and injected into the indicated mice, and 18 hours later 
the ratio between different populations was determined by flow 
cytometry, gated on CD45.1+ cells. The percentage of specific 
killing is indicated. In some experiments, only pIV-specific CTLs 
were analyzed. (A) Gating for the injected CD45.1+ spleen cells 
and one representative example per experimental group is 
shown for the simultaneous detection of pIV and dbp43 CTLs. 
Naive 8- to 12-week-old B6 (N), immunized 8- to 12-week-old 
B6 (I), and 8- to 12-week-old LoxP-TAg (Tg) mice 2, 4, 6–10, 
and 12–35 weeks after Ad.Cre injection were analyzed. Immu-
nization of B6 mice was performed either by single i.p. injection 
of 0.5 × 107 to 1 × 107 16.113 cells or simultaneous injection of 
16.113 cells (i.p.) and 1 × 109 PFUs Ad.Cre (i.v.). (B) The com-
bined data of pIV-specific kill are shown. White circles represent 
LoxP-TAg mice with liver tumors larger than 5 mm in diameter. 
Black circles represent B6 and LoxP-TAg mice with no tumors 
or LoxP-TAg mice with liver tumors smaller than 5 mm in diam-
eter. Each symbol represents 1 mouse; horizontal bars indi-
cate mean values. Some of the B6 mice were injected with 
16.113 only (asterisk). The P value at the top left of the graph 
represents overall significance calculated by Krusal-Wallis test. 
(C) The combined data of dbp43-specific kill are shown. Each 
symbol represents 1 mouse; horizontal bars indicate mean val-
ues. The P value at the top left of the graph represents overall 
significance calculated by Krusal-Wallis test.
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activity was detected in mice with large tumor burdens, suggesting 
that the progressing HCC upregulated CTL activity in the spleen 
(Figure 3B, white circles). CTLs specific for the adenovirus protein 
DNA-binding protein 43 (dbp43) were also induced upon Ad.Cre 
infection and were detectable by in vivo kill analysis throughout 
the experiment (Figure 3C).
As a more rigorous test for functional pIV-specific CTLs, 
HCC-bearing LoxP-TAg and — as controls — Rag-2–deficient mice, 
young LoxP-TAg mice, and old LoxP-TAg mice with sporadic 
tumors were challenged s.c. with the TAg-expressing tumor cell line 
16.113 (Table 1). Whereas in Rag-2–deficient mice tumors grew, 
most LoxP-TAg mice infected with viruses 4, 8, and 24 weeks before 
(22 out of 24 mice) rejected the transplanted tumor cells, while the 
primary TAg+ HCC progressed. In accordance with previous obser-
vations, LoxP-TAg mice with sporadic tumors did not reject 16.113 
cells, whereas young LoxP-TAg mice rejected the transplanted 
tumor cells. Thus, TAg-specific CTLs, functionally activated upon 
virus-mediated TAg expression, were not systemically tolerized by 
the progressing HCC. Furthermore, the few TAg+ cells that escaped 
elimination after viral infection “sneaked through” in the presence 
of functionally activated pIV-specific CTLs.
Virus-induced HCCs are regressors upon transplantation. Since HCCs 
progressed despite tumor immunity, we asked whether the HCCs 
were selected for low immunogenicity. Western blot analysis 
revealed that primary cell lines derived from HCCs of virus-in-
fected LoxP-TAg mice expressed similar amounts of TAg when 
compared to the sporadic tumor line 16.113 and HCC cell lines 
that had been obtained from neonatal TAg-tolerant LoxP-TAg 
× Alb-Cre mice (Figure 4A). In order to determine the immuno-
genicity of TAg+ HCC cell lines, B6 mice were immunized with 
cells of the respective HCC lines, and in vivo kill analysis was 
performed. A vigorous pIV-specific CTL response to all HCC cell 
lines was induced irrespective of whether they were obtained from 
virus-infected LoxP-TAg or TAg-tolerant LoxP-TAg × Alb-Cre 
mice (Figure 4B). The efficacy of TAg-specific CTL killing induced 
by the HCC lines was comparable to that induced by the sporadic 
regressor cell line 16.113. Importantly, all HCC lines used for in 
vivo kill analysis grew in immune-deficient Rag2–/– mice but were 
rejected when transplanted into immunocompetent B6 mice (Fig-
ure 4B). Therefore, no selection for low immunogenicity occurred 
in TAg-expressing HCC, despite the persistent presence of func-
tional pIV-specific CTLs.
Virus-induced HCCs induce antigen-specific local tolerance. The previ-
ous experiments raised the question of how the HCCs, regressors 
upon transplantation, could progress in the presence of functional 
pIV-specific T cells. Histopathological examination of livers from 
nontreated and Ad.Cre-infected LoxP-TAg mice at different time 
points thereafter revealed moderate infiltration of the tumor nod-
ules by CD3+ T cells (Figure 5A). Quantitative analysis of CD3+ 
T cell infiltration revealed significantly higher infiltration of small 
tumor nodules that developed 6–10 weeks after Ad.Cre infection 
in comparison with that of end-stage HCCs in mice 12–35 weeks 
after Ad.Cre infection. Peritumoral CD3+ T cell infiltration in end-
stage tumors was only slightly higher (statistically not significant) 
than intratumoral infiltration (Supplemental Figure 6). Whereas 
FoxP3+ cells were not detected (Figure 5A), F4/80+ cells, compris-
ing macrophages and Kupffer cells, were equally distributed in 
the livers of naive and virus-infected mice (Figure 5A, weeks 0–4) 
but were decreased in cancerous tissue (Figure 5A, weeks 6–10 
and 12–35). Solid tumors are supposed to create an immune-
suppressive environment. We detected CD163+ M2 macrophages, 
FAP+ stromal cells, and CD11b+/Gr-1+ immature myeloid cells in 
end-stage HCC (Supplemental Figure 7). Therefore, these compo-
nents potentially could contribute to local immune suppression. 
To analyze local T cell function in HCC, 16.113 cells, transduced 
to express luciferase (Fluc) and EGFP (16113gl), were injected into 
the livers of virus-induced HCC-bearing LoxP-TAg mice, and mice 
were observed until they had to be sacrificed due to primary HCC 
burden. Histological analysis of liver sections revealed the growth 
of 16.113gl tumors with the typical ductal appearance of this (gas-
trointestinal-derived) tumor, TAg-specific staining, and absence 
of the liver/HCC-specific marker HepPar1 in both HCC-bearing 
LoxP-TAg and Rag2–/– mice (Figure 5B). Age-matched tumor-free 
LoxP-TAg mice rejected 16.113gl cells injected into the liver (data 
not shown). Because 16.113 cells were rejected in HCC-bearing 
mice at a s.c. injection site (Table 1), the data demonstrate local 
tolerance in HCC-bearing LoxP-TAg mice.
16.113 cells were transduced to express luciferase and EGFP 
(16113gl) not only to visualize tumor growth but also to express 
foreign antigens in the tumor cells. This allowed us to ask whether 
tolerance in the tumor microenvironment was specific for TAg, the 
dominant transplantation rejection antigen in TAg-transformed 
tumors (8), or whether CTLs were suppressed independent of 
their specificity. First, 16113gl cells were injected s.c. to analyze 
whether variants that lost the marker proteins (or the coexpressed 
selectable markers neomycin and hygromycin) could be selected 
in suitable hosts. In Rag2–/– mice, tumors grew and retained Fluc 
expression, as detected by BL imaging (Figure 5C). In LoxP-TAg 
× Alb-Cre mice, which are TAg tolerant but generate normal 
CTL responses to other antigens (31), Fluc (and EGFP; data not 
shown) signals became undetectable within 2 to 3 weeks (Figure 
5, C and D), while TAg+ tumors progressed after a short selection 
phase (Figure 5D). In young LoxP-TAg mice, 16113gl tumors were 
rejected. Compatible with previous experiments, in old LoxP-TAg 
mice with sporadic tumors, which had developed TAg tolerance 
and CTL hyporesponsiveness to unrelated antigens (31), 16113gl 
Table 1
LoxP-TAg mice with Ad.Cre-induced HCC reject s.c. transplanted 
TAg+ tumor cells
Genotype Time after  Tumor Time observed 
 Ad.Cre (wk) takeA (wk)B
Rag2–/– – 3/3 [5, 6, 6]C
Young Tg – 0/4 30, 30, 30, 30D
Tg, sporadic – 2/2 [5, 8]C
Tg 4 2/13 10, 12, 18, 18, 18, 19, 19,  
   20, 22, 25, 29, [10, 11]C
Tg 8 0/8 8, 8, 10, 10, 14, 14, 16, 20
Tg 24 0/3 8, 10, 12
1 × 106 TAg+ 16.113 cells were injected s.c. into untreated 8- to 12-week-
old Rag-2–deficient mice, LoxP-TAg mice (Young Tg), LoxP-TAg mice 
bearing large sporadic tumors (Tg, sporadic), and LoxP-TAg mice that 
had been injected with Ad.Cre when they were 8–12 weeks old (Tg). 
Tumor growth was followed using calliper measurement. AThe number 
of mice with challenge tumor per mice in experiment is shown. Mice 
were observed until Bthey had to be sacrificed because of primary HCC 
or Cchallenge tumor grew to an average size of at least 6 mm in diame-
ter (for these mice, time to growth of transplanted tumor cells is given in 
brackets). DYoung LoxP-TAg mice observed for the indicated time were 
tumor free.
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tumors grew progressively, while retaining the Fluc signal, albeit 
at reduced level (Figure 5, C and D). These data show that antigen 
loss variants can be selected but not in mice with nonvirus-induced 
sporadic cancer, leading to impaired CTL responses against unre-
lated antigens. Remarkably, if 16113gl cells were injected intrahe-
patically (i.h.) into LoxP-TAg mice with virus-induced HCC, Fluc 
signals were lost within 2 to 3 weeks (Figure 5E and Supplemental 
Figure 8), and antigen loss variants progressed (Figure 5B). These 
data demonstrate that, in LoxP-TAg mice with virus-induced HCC, 
local tolerance is specific for the tumor transplantation rejection 
antigen TAg and that foreign antigens were still selected against in 
the tumor microenvironment.
Local tolerance is mediated by PD-1/PD-L1 dependent and indepen-
dent mechanisms. pIV-specific CD8+ T cells in livers and spleens of 
LoxP-TAg mice with virus-induced HCC were analyzed with Kb/IV 
tetramers. A high frequency of the CD8+ T cells in the livers 
of HCC-bearing LoxP-TAg mice were pIV specific (14%–31% 
Kb/IV-tetramer+ cells of the CD8+ T cells) but not in age-matched 
nontreated LoxP-TAg mice (Figure 6A). The frequency of Kb/IV- 
tetramer+ CD8+ cells in the spleens of HCC-bearing LoxP-TAg 
mice was 5%–6%, whereas it was undetectable in the control mice. 
Importantly, programmed cell death protein-1 (PD-1) receptor was 
expressed on almost all Kb/IV-tetramer+ CD8+ T cells in the liver 
(Figure 6B). PD-1 expression was higher on liver compared with 
that on spleen pIV-specific CD8+ T cells (Supplemental Figure 9). 
All virus-induced HCC cell lines investigated expressed the ligand 
PD-L1, whereas hepatocytes from noninfected LoxP-TAg mice did 
not (Figure 6C). In addition, immunohistochemical analysis of liv-
ers from HCC-bearing LoxP-TAg mice showed PD-L1 expression 
on TAg-positive carcinoma cells and TAg-negative stromal cells 
(Supplemental Figure 10). Notably, intrahepatic CD11c+, CD68+, 
and Gr-1+ cells showed upregulation of PD-L1 when HCC-bearing 
LoxP-TAg mice 10–20 weeks after Ad.Cre infection were compared 
with untreated age-matched LoxP-TAg mice (Supplemental Fig-
ure 11). The sporadic tumor cell line 16.113 that grew in livers of 
HCC-bearing mice also expressed PD-L1 (Figure 6C).
Previous studies suggested that accessibility of T cells to the liver 
and lack of local inflammation prevented T cells from inducing 
autoimmunity and liver damage (33). If such a mechanism would 
be operative in our model, blockade of PD-1 should not be effective. 
To test this possibility, we blocked PD-1/PD-L1 interactions. LoxP- 
TAg mice with HCC 12 weeks after virus infection were treated with 
anti–PD-L1 antibodies for 2 weeks, revealing a significant delay in 
HCC progression when compared with mice that received isotype 
control antibodies (Figure 6D). The data are in agreement with 
data in HBV transgenic mice showing functional suppression of 
virus-specific CD8+ T cells by PD-1/PD-L1 interaction (34). How-
ever, this study left open whether other mechanisms contributed to 
CD8+ T cell suppression and whether PD-1+CD8+ T cells could sup-
press primary PD-L1+ HCC in a permissive host. We also analyzed 
pIV-specific CD8+ T cells in the liver for the presence of other inhib-
itory receptors involved in T cell exhaustion, namely Lag3, Tim-3, 
and CD160. We found that a high proportion of intrahepatic pIV- 
specific CD8+ T cells expressed Lag3, CD160, and, occasionally, 
Tim-3 (Supplemental Figure 12). Next, we transferred spleen or 
CD8+ T cells from LoxP-TAg mice with virus-induced HCC, which 
express PD-1 on almost all pIV-specific CD8+ T cells (Figure 6B), 
into LoxP-TAg mice with virus-induced HCC after irradiation. Two 
weeks after treatment, mice with both spleen (Figure 6E) and CD8+ 
T cell transfer (Figure 6F) and irradiation controls showed liver 
damage, as detected by increasing ALT and AST levels in the serum, 
likely due to irradiation (Supplemental Figure 13). Whereas in the 
irradiated control mice, ALT and AST levels further increased and 
mice rapidly succumbed to HCC, liver enzymes in immune cell–
treated mice declined to slightly elevated levels in comparison with 
nontreated age-matched LoxP-TAg mice (Supplemental Figure 13). 
Spleen and CD8+ T cell transfer substantially delayed HCC progres-
sion when compared with that in the irradiated control mice (Fig-
ure 6, E and F). Then, we repeated the experiment but treated LoxP- 
TAg mice 1, 7, and 19 weeks after virus infection. In mice treated 
1 week and 19 weeks after viral infection the therapy was ineffective 
(Supplemental Figure 14, A and C). Probably, the few TAg+ cells 
that survived clearance of most infected cells in the acute phase 
also escaped the transferred T cells. Nineteen weeks after viral infec-
tion, HCC was apparently too advanced for treatment. Treatment 
Figure 4
Transplanted Ad.Cre-induced HCCs from LoxP-TAg mice are as 
immunogenic as those from TAg-tolerant LoxP-TAg × Alb-Cre mice. 
(A) Similar TAg expression in HCC lines derived from Ad.Cre-treated 
LoxP-TAg mice and LoxP-TAg × Alb-Cre mice. Western blot analysis 
of TAg expression in primary HCC lines derived from Ad.Cre-treated 
LoxP-TAg mice (Ad.56, Ad.451, Ad.434) and LoxP-TAg × Alb-Cre mice 
(Alb.7, Alb.14). Sporadic TAg+ tumor line 16.113 was used as a control. 
20 μg protein was separated by SDS-PAGE gel, blotted onto nitrocellu-
lose membrane, and incubated with anti-TAg antibodies. After autora-
diography, the membrane was stripped and reprobed with anti–β-actin 
antibodies as loading control. The lanes were run on the same gel but 
were noncontiguous. (B) TAg+ HCC lines induced pIV-specific CTLs. 
1 × 106 cells of tumor lines 16.113 and HCC lines as indicated were 
injected s.c. into B6 mice, and 10 days later pIV-specific in vivo kill was 
assays were performed as in Figure 3. The percentage of specific killing 
of peptide-loaded cells is indicated. Each symbol represents 1 mouse; 
bars indicate mean values. The P value represents overall significance 
of the graph calculated by Krusal-Wallis test. In a separate experiment, 
1 × 106 TAg+ HCC cells and, as a control tumor line, 16.113 cells, were 
injected s.c. into untreated 8- to 12-week-old Rag-2–deficient and immu-
nocompetent B6 mice. Tumor growth was followed using calliper mea-
surement. Shown is the number of mice that rejected challenge tumor 
per mice in experiment. Mice were observed until challenge tumors 
grew up to an average size of at least 10 mm in diameter. Mice that 
rejected the transplanted tumor cells were observed for at least 90 days.
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7 weeks after viral infection (Supplemental Figure 14B) was simi-
larly effective as that after 12 weeks (Figure 6, E and F). Together, 
both PD-1/PD-L1–dependent and –independent mechanisms 
appear to contribute to local tolerance. Furthermore, PD-1+CD8+ 
T cells have the potential to eliminate HCC in conditioned hosts.
Discussion
We established a model that recapitulates several features of 
virus-induced HCC in humans. A strong viral antigen, for which the 
mice were not tolerant at young age, was activated and recognized 
by T cells during viral infection of hepatocytes. The virus infection 
induced an antiviral response concomitant with a rapid and strong 
response against TAg, the cancer-driving oncogene, due to stop cas-
sette deletion in the infected hepatocytes. T cell recognition resulted 
in hepatitis and clearance of the infected TAg+ cells, at least the vast 
majority. Because adenoviruses do not replicate in mice, we ensured 
that the very few remaining TAg+ hepatocytes escaped elimination 
and were not induced by virus spread. It remains enigmatic why 
these few TAg+ hepatocytes survived, while neighboring infected 
TAg+ cells were eliminated. They could have expressed less TAg dur-
ing the effector CTL response (35), deleted the stop cassette when 
effector CTLs already went through the contraction phase (36), or 
reflected a subtype of hepatocytes that are resistant to elimination 
(37, 38). Strikingly, the few TAg+ hepatocytes that sneaked through, 
despite functionally activated TAg-specific CTLs, were recognized 
at some point and upregulated systemic tumor immunity, at least 
at sites distant from the primary tumor, while progressing to lethal 
HCC. Sneaking through has been described previously in tumor 
transplantation models, in which low numbers of injected tumor 
cells remained unrecognized for too long by T cells (39). Sneaking 
through had not been demonstrated before in a primary tumor 
model in the presence of functionally activated CTLs.
Our data illustrate the fundamentally different immune response 
to sporadic and virus-induced tumors, directed against the same 
antigen in the same mouse model. If left untreated, LoxP-TAg mice 
develop in a stochastic manner sporadic tumors late in life after a long 
premalignant phase (8, 31). TAg recognition in mice with premalig-
nant lesions, as detected by the generation of anti-TAg IgG antibod-
ies, induced CTL tolerance, and no transient phase of functional acti-
vation was detected (31). In sharp contrast, if TAg was recognized by 
T cells during viral infection, anti-TAg antibodies were of partially dif-
ferent IgG subtype, indicating already the qualitatively different adap-
tive immune response. More importantly, in the viral context, CD4+ 
and CD8+ T cells were functionally activated and substantially delayed 
HCC progression. The response was primarily directed against TAg, 
because TAg-tolerant mice rapidly succumbed to HCC. In contrast to 
(nonvirus-induced) sporadic tumors, the virus-induced HCC needed 
to escape immune control. Immune escape did not involve systemic 
CTL tolerization or the apparent selection of low immunogenic vari-
ants. However, the observation that HCCs, progressors in the primary 
host with systemic tumor immunity, were regressors in transplanta-
tion experiments raises doubts about the ability of this assay to mea-
sure immune selective processes in the primary host.
There is ample evidence that solid tumors create an immune-sup-
pressive microenvironment (40, 41). Therefore, it may not be surpris-
ing that transplanted TAg+ tumor cells, which were rejected at a dis-
tant site, a phenomenon termed concomitant immunity (42), grew 
in the livers of HCC-bearing mice. Because most described immune-
suppressive mechanisms, e.g., those mediated by indoleamine 
2,3-dioxygenase, TGF-β1, FAP-expressing cells, M2 macrophages, 
or CD11b+Gr1+ cells (43–47), act nonspecifically, one would have 
expected that tumor-unrelated T cell responses were also suppressed 
within the suppressive tumor microenvironment. Remarkably, trans-
planted tumor cells were selected against expression of foreign anti-
gen but not TAg in the livers of HCC-bearing mice, demonstrating 
local tolerance specifically for the rejection antigen of HCC. Toler-
ance required the presence of HCC, because young untreated LoxP- 
TAg mice rejected TAg+ tumor cells injected into the liver. Our data 
contrast those obtained in a tumor transplantation model, suggest-
ing that tumors are a privileged site for bacterial growth (48). Because 
of the rapid growth of the transplanted tumor, bacterial accumula-
tion could be observed for only 6 days after intratumoral injection. 
Therefore, it is not clear whether an innate or adaptive immune 
response was impaired and whether the bacteria would have been 
eliminated at a later time point. This model is also difficult to com-
pare to ours, because the bacteria, Listeria monocytogenes, reside inside 
macrophages and CD4+ T cells are mainly responsible for protection.
The virus-induced HCC used at least 2 independent mechanisms 
of local tolerance, each of which was necessary for unimpaired pro-
gression. PD-1, expressed by almost all TAg-specific CD8+ T cells 
in HCC-bearing mice, and PD-L1, expressed by the HCC, together 
with the observation that a brief treatment with anti–PD-L1 block-
ing antibodies substantially delayed HCC progression, reveal the 
first immune escape mechanism. We cannot exclude a contribution 
of PD-L1 expression by tumor stroma cells for T cell inhibition. 
This appears even likely, because various tumor stroma cell types 
expressed PD-L1 (49–52). PD-1 expression by CD8+ T cells has been 
associated with cellular exhaustion in models of persistent viral 
infection (6, 53). Even though we cannot rule out some functional 
impairment of the TAg-specific PD-1+CD8+ T cells (5), they exhibited 
undiminished CTL activity in vivo, rejected TAg+ tumor cells injected 
at a s.c. site and, importantly, inhibited autochthonous HCC pro-
gression upon transfer into sublethally irradiated mice. In fact, CTL 
activity was upregulated as HCC progressed and antigen amount was 
increased. Thus, while PD-1/PD-L1 interaction was clearly involved 
in local immune suppression, it was not sufficient to constrain HCC 
progression. We found additional inhibitory receptors, Lag3, CD160, 
Figure 5
Ad.Cre-induced HCCs in LoxP-TAg mice cause antigen-specific local 
tolerance. (A) HCC tissues were stained for CD3, F4/80, and FoxP3 
expression. Arrows indicate a small TAg+ lesion (also depicted in Fig-
ure 1D). One representative out of three experiments per time point is 
shown. (B) 1 × 106 TAg+ 16.113gl cells were injected i.h. into Rag2–/– and 
HCC-bearing LoxP-TAg mice, and 7–12 weeks later liver tissues were 
stained for TAg and HepPar1. HepPar1-negative areas indicate 16.113 
tumors (asterisks). Note that tumors grew in both groups of mice. Scale 
bar: 100 μm (A and B). (C) Selection of antigen-loss variants of 16.113gl 
cells in LoxP-TAg × Alb-Cre but not Rag2–/– mice. LoxP-TAg × Alb-Cre 
(6 weeks), young LoxP-TAg (8 weeks), large tumor-bearing LoxP-TAg 
(95 weeks), and Rag2–/– mice (8–12 weeks) injected s.c. with 1 × 107 
16113gl cells were analyzed by BL imaging and tumor growth. Nontreated 
mice injected with luciferin served as controls (–; bkg ctrl). Images are 
representative for 2 experiments. (D) Tumor growth and Fluc signals of 
mice shown in C. Data shown are combined from 2 experiments; error 
bars represent SEM. Age and number of mice are shown in parenthesis. 
(E) Loss of BL signal of i.h. injected 16.113gl cells in HCC-bearing LoxP- 
TAg mice, but not in Rag2–/– mice, 2–6 months after Ad.Cre infection, as 
detected by BL imaging. Representative Rag2–/– (s.c., n = 2; i.h., n = 4) 
and HCC-bearing mice (i.h., n = 14) 7 weeks after 16.113gl cell injection 
are shown. See also Supplemental Figure 8.
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One could have expected that tumor development in the liver, as a 
supposedly tolerogenic organ, rather than in the lung would have 
induced systemic tolerance, yet the opposite was the case. The high 
immunogenicity and the high infection rate of the adenovirus com-
pared with that of the lentivirus may explain the different results. 
Thus, the adenovirus may act as stronger adjuvant to activate 
TAg-specific T cells compared with the lentivirus that helps the 
activation of the chosen model antigens SIY and ovalbumin (59, 
60). Two reasons may explain the different mechanisms of immune 
escape in the HCC model (retention of the target antigen/high 
immunogenicity and local tolerance) versus the sarcoma model 
(loss of target antigen and selection for low immunogenicity). 
Sequences introduced into cells by viral infection may be silenced 
easier by epigenetic mechanisms than sequences introduced into the 
germline. More importantly, in the HCC model, the T cell response 
was directed against the cancer-driving oncogene, which cannot 
be easily selected against (61), while, in the sarcoma model, the 
T cell response was directed against surrogate antigens, which better 
reflect passenger mutations and can be easily selected against (60).
Because HCC progresses in a great proportion of patients with 
chronic HCV infection, despite the presence of HCV-specific CD8+ 
T cells (15–17, 62), and the liver-infiltrating CD8+ T cells in these 
patients expressed PD-1 (63), we think that our model encom-
passing both initial anti-virus immune response and HCC devel-
opment bears high similarity to the human disease.
Methods
Mice. LoxP-TAg, Alb-Cre × LoxP-TAg, and Vil-Cre × LoxP-TAg transgenic 
mice were described previously (8, 31, 32). Rag2–/– mice (B6.129S6-Rag2tm1Fwa) 
and Rag2–/–cg–/– mice (C57BL/6J × C57BL/10SgSnAi)-[KO]γc-[KO]Rag2) 
were purchased from Taconics Farms; Cd4–/– mice (B6.129S2-Cd4tm1Mak/J) 
and Cd8–/– mice (B6.129S2-Cd8atm1Mak/J) were purchased from The Jackson 
Laboratory; B6 mice were obtained from Charles River; and CD45.1 con-
genic mice were bred in our animal facilities.
Immunization/tumor cell transplantation. For TAg-specific immunization, 
mice were injected i.p. with 5 × 106 to 10 × 106 TAg+ 16.113 tumor cells. 
Adenovirus-specific immunization was performed by i.v. injection of 
1 × 109 PFUs of Ad.Cre. For tumor challenge experiments and analysis of 
TAg-specific CTL response, mice were injected s.c. with 1 × 106 cells of the 
indicated cell lines: 16.113 is a tumor cell line that developed spontane-
ously in the gastrointestinal tract of a LoxP-TAg mouse (8), HCC cell lines 
Ad.56/Ad.451/Ad.434 were obtained from LoxP-TAg mice 5–6 months after 
Ad.Cre administration, and HCC cell lines Alb.7/Alb.14/Alb.346 were iso-
lated from 3-month-old LoxP-TAg × Alb-Cre mice (31). For analysis of local 
tolerance in the liver, 16.113 cells were retrovirally transduced with pLGSN 
and subsequently transfected with pCAG-Fluc generating cell line 16.113gl. 
For selection of transduced and transfected clones neomycin and hygromy-
cin resistance markers were used, respectively. 1 × 106 16.113gl cells (bulk 
culture) expressing EGFP and Fluc were injected into the liver parenchyma, 
and growth of 16.113gl cells was determined by histology of liver tissue sec-
tions. Tumor volume in mice injected s.c. with 1 × 107 16.113gl cells into 
the flank was determined by caliper measurement of the tumor parameters 
(x,y,z) according to the formula (xyz)/2. Animals that rejected the challenge 
tumors were monitored for at least 60 days.
In vivo kill assays. CTL activity against the TAg-specific pIV (VVYD-
FLKL; ref. 8) was analyzed in vivo separately or simultaneously with the 
adenovirus dbp43 (FALSNAEDL; ref. 64). Single pIV-specific in vivo kill 
assay was performed as previously described (8). For simultaneous detec-
tion of CTL activity against pIV and dbp43, nonloaded (Ø)and pIV- and 
dbp43 peptide–loaded (1 μM each) CD45.1+ congenic spleen cells (1 × 107 
and, occasionally, Tim-3, being expressed on pIV-specific T cells in 
the liver that could further contribute to T cell dysfunction in the 
liver (54–56). T cell accessibility of the HCC appeared to be a second 
mechanism impeding tumor immunosurveillance. It has been pro-
posed that infiltration of adoptively transferred T cells in an auto-
immune hepatitis model was facilitated by irradiation (57). Consis-
tent with these data, the transfer of CD8+ T cells from HCC-bearing 
mice, which contained TAg-specific CD8+ T cells that basically all 
expressed PD-1+, into irradiated HCC-bearing mice also substantially 
inhibited HCC progression. Virus-induced HCC in untreated mice 
contained fewer CD3+ T cells in comparison with sporadic premalig-
nant lesions of LoxP-TAg mice that had already developed CTL tol-
erance (31). Collectively, our data suggest a 2-stage immune evasive 
mechanism of HCC: T cells can only poorly infiltrate HCC, and the 
few infiltrating T cells are locally inhibited in their function. Block-
ing functional inhibition (through anti–PD-L1 antibodies) or allow-
ing better T cell infiltration (through irradiation) overcomes local 
tolerance, albeit not long term.
While it has long been accepted that virus-associated cancers are 
under effective immunosurveillance (58), the mechanism of escape 
from immunosurveillance may be manifold and depend on the 
experimental or clinical situation. This is nicely illustrated by com-
parison of our model with a model published recently, in which len-
tiviruses were used to deliver neoantigens into cells, simultaneously 
deleting the p53 tumor suppressor and activating oncogenic Ras 
by Cre recombinase technology (59, 60). Depending on the site of 
tumor development, CTLs were either inefficiently activated (car-
cinomas in the lung) or efficiently activated CTLs selected antigen 
loss variants through epigenetic silencing (sarcomas in the muscle). 
The lentiviral and the adenoviral system presented here have com-
mon and distinct features, which together give important insight by 
which mechanism tumors escape under varying conditions. Both 
models have in common that the tumor antigen was expressed at 
the time of tumor initiation and was rapidly recognized by T cells 
during viral infection. On the other hand, both models likely dif-
fer by virus immunogenicity and infectivity, type of target antigen, 
mode of target antigen activation, and site of tumor development. 
Figure 6
Local tolerance is mediated by PD-1/PD-L1–dependent and –inde-
pendent mechanisms. (A) Spleen and liver cells from nontreated and 
HCC-bearing LoxP-TAg mice 27 weeks after Ad.Cre infection were 
analyzed for CD8 expression and Kb/IV tetramer binding. Represen-
tative plots (n = 3; range from 14%–31% double-positive cells) are 
shown. (B) CD8+ T cells as in A were analyzed for PD-1 expression and 
Kb/IV tetramer binding. Representative plots (n = 4; 7%–23% of Kb/IV 
tetramer+ CD8+ T cells expressed PD-1) are shown. (C) Hepatocytes 
from nontreated LoxP-TAg mice (liver), HCC line Ad.56, and 16.113 
cells were stained with isotype control or anti–PD-L1 antibodies. Rep-
resentative plots (n = 4) are shown. (D) HCC-bearing LoxP-TAg mice 
12 weeks after Ad.Cre infection received anti–PD-L1 (red line, n = 5) 
or isotype control antibody (black line, n = 5) for 2 weeks, and survival 
was monitored. One of two experiments with comparable results is 
shown. (E) HCC-bearing LoxP-TAg mice 14 weeks after Ad.Cre injec-
tion (red line, n = 6) received irradiation (5 Gy) and 5 × 106 spleen 
cells from Ad.Cre-treated HCC-bearing LoxP-TAg mice (18 weeks after 
Ad.Cre injection) or were left untreated (black line, n = 5), and sur-
vival was monitored (see also Supplemental Figure 14B). (F) Irradiated 
HCC-bearing LoxP-TAg mice 16 weeks after Ad.Cre injection (red line, 
n = 11) were treated with 1 × 106 CD8+ T cells obtained from mice as 
in E or left untreated (black line, n = 4), and survival was monitored. 
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BL imaging. Mice were injected i.p. with 3 mg d-luciferin (Biosynth) dis-
solved in PBS (30 mg/ml). 10 minutes later, mice were anesthetized with iso-
flurane, and BL image acquisition was performed using an exposure time of 
180 seconds. BL imaging data were analyzed with the Living Image software 
(Caliper Life Science). For detection of adenovirus tropism, an adenovirus 
expressing the firefly luciferase under the control of the CMV promoter (Ad.
Luc), provided by M. Zenke (Institute for Biomedical Engineering, Cell Biol-
ogy, Aachen University Medical School, RWTH Aachen, Germany), was used.
Western blot analysis. Proteins were quantified with the Bio-Rad protein 
assay. 40 μg protein extract was loaded onto a NuPage Tris-acetate 3%–8% 
SDS-PAGE gel (Invitrogen) and blotted on a polyvinylidene fluoride mem-
brane (Amersham Biosciences) using the XCell II blot module (Invitrogen). 
After blocking with 5% dried skim milk, the blot was incubated with anti-
TAg IgG2a antibody (Ab-2, Calbiochem), washed with PBS containing 
0.5% Tween, and subsequently incubated with HRP-labeled anti-mouse 
IgG2a antibody (BD Biosciences). Visualization was performed using the 
ECL Detection Kit (Amersham Biosciences) according to the manufac-
turer’s instructions and the LUMI-F1 Imaging Workstation (Roche). To 
confirm loading of equal amounts of protein, the blot was reprobed with 
anti–β-actin antibody (Abcam), followed by HRP-labeled goat anti-rabbit-
IgG (BD Bioscience), and detected as described above.
Primary tumor induction. For HCC induction, LoxP-TAg mice (8) were 
infected with 1 × 109 PFUs of Cre recombinase–expressing adenoviruses 
(Ad.Cre) by tail vein injection (i.v.).
PD-L1 mAb treatment. For in vivo antibody blockade, 200 μg rat anti-
mouse PD-L1 (10F.9G2; Bio X Cell) and rat IgG2b isotype control (LTF-2; 
Bio X Cell) were injected i.p. into the indicated mice every third day for 
2 weeks as described previously (7), and HCC development was monitored.
Adoptive immune cell transfer. For adoptive cell transfer, splenic CD8+ 
T cells were purified by use of the CD8α+ T Cell Isolation Kit II (Miltenyi 
Biotec). 1 × 106 purified CD8+ T cells (80%–95% purity) were injected i.v. 
into irradiated (5 Gy) HCC-bearing LoxP-TAg mice. For spleen cell transfer, 
single cell suspensions were prepared, and 5 × 106 cells were transferred i.v.
Statistics. Statistical analyses were performed using SPSS and Prism (Graph-
Pad) Software. The overall significance of each graph was calculated with the 
Kruskal-Wallis test. Comparisons of 2 groups were done by Mann-Whitney 
U test. Survival curves were compared by Gehan-Breslow-Wilcoxon test. 
P values of less than 0.05 were regarded as statistically significant.
Study approval. Animal experiments were performed according to and 
with approval of Landesamt für Gesundheit und Soziales, Berlin, Germany.
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each) were labeled with CFSE in a final concentration of 0.75 μM (CFSEhi), 
0.075 μM (CFSEint), or 0.0075 μM (CFSElo), respectively. A total of 3 × 107 
mixed cells at a 1:1:1 ratio were injected i.v. into the indicated mice. 18 
hours later, spleens of recipient mice were stained with APC-labeled anti-
CD45.1 antibodies (A20, BD Pharmingen) to separate CFSE-labeled cells. 
The ratios among the 3 populations were determined by flow cytometry, 
and the specific cytolytic activity was calculated as follows: percentage 
of specific killing = (1 – [ratio of control mice/ratio of immunized] or 
1 – [ratio of control mice/Ad.Cre-injected mice] × 100), where the ratio is 
the percentage of CFSElo/CFSEhi or CFSElo/CFSEint.
ELISA. Serum samples from individual mice were collected. For detection 
of anti-TAg antibody, ELISA plates, coated with TAg protein, were used as 
described previously (8). Mouse TAg antibody (PAb 100; BD Pharmingen) 
was used as standard. TAg-specific IgG1, IgG2a, IgG2b, and IgG3 were 
determined in serum samples, obtained from individual mice. The mouse 
immunoglobulin screening/isotyping kit (Zymed Laboratories Inc.) was 
used according to the manufacturer’s instructions.
Histology and immunohistochemistry. During autopsies of LoxP-TAg mice, 
whole organs or macroscopically detectable tumor tissues were embedded 
in paraffin. Serial sections (2–4 μm) were mounted on slides and stained 
with hematoxylin and eosin. For immunostaining, consecutive slides were 
subjected to a heat-induced epitope retrieval step before incubation with the 
following antibodies: mouse anti–SV40 large T, small t antigen (PAb 108; 
BD Pharmingen), Ki-67 (TEC-3, Dako), CD3 (N1580, Dako), FoxP3 (FJK-
16s, eBioscience), F4/80 (BM8, eBioscience), CD163 (M-96, Santa Cruz 
Biotechnology), fibroblast activation protein (FAP; Abcam), and HepPar1 
(OCH1E5.2.10, Dako). For detection, the Streptavidin-AP Kit (K5005, Dako) 
alone or biotinylated donkey anti-rat (Dianova) or rabbit anti-rat (Dako) 
secondary antibodies were used followed by the Streptavidin-AP Kit or the 
EnVision Peroxidase Kit (K 4010, Dako). Alkaline phosphatase (AP) and 
peroxidase were developed by Fast Red as chromogen or diaminobenzidine 
chromogenic substrates, respectively. For double immunofluorescence stain-
ing, 5-μm cryosections were incubated first with FITC-labeled mouse anti–
SV40 large T, small t antigen (PAb 108; BD Pharmingen) antibody. After 
washing 3 times in PBS, sections were incubated with anti-mouse PD-L1 
(10F.9G2, BioLegend). After another washing step, sections were stained 
with Alexa Fluor 594–labeled donkey anti-rat antibody. Nuclei were coun-
terstained using VECTASHIELD Hard+Set Mounting Medium with DAPI 
(Vector Laboratories). Images were acquired using a fluorescence microscope 
(AxioImager) equipped with a CCD camera (AxioCam MRm) and processed 
with ApoTome and ZEN software (Carl Zeiss MicroImaging Inc.).
Flow cytometry. Single cell suspensions of spleen cells were stained with 
PE-labeled Kb/pIV tetramers (Beckman Coulter), PerCP-labeled rat anti-
mouse CD8a antibody (53-6.7; BD Pharmingen), APC-labeled hamster 
anti-mouse CD3a antibody (145-2C11; BD Pharmingen), APC-labeled 
hamster anti-mouse CD279 antibody (J43; BD Pharmingen), PerCP-eFluor 
710-labeled anti-mouse CD223 (Lag3, C9B7W; eBioscience), Alexa Fluor 
647–labeled anti-mouse Tim-3 (B8.2C12, BioLegend), and eFluor 660–
labeled anti-mouse CD160 (CNX46-3; eBioscience). For analysis of hepatic 
lymphocytes and hepatocytes, livers were perfused with PBS, collagenase 
digested (1 mg/ml, 4 hours, 37°C), washed twice, and subsequently incu-
bated with the antibody indicated above or PE-conjugated rabbit anti-mouse 
CD274 (MIH5; BD Pharmingen) and isotype-matched control antibody.
In vivo MRI. MRI experiments were performed with a 1.5-T clinical 
MRI instrument (Magnetom Symphony Maestro Class, Siemens), with 
either a CP-Breast Array or a Flex Loop Small surface coil (Siemens) as 
previously described (31).
Detection of liver enzymes. The transaminases ALT and AST were used 
as indicators for liver damage. Serum samples, mixed with Heparin, 
were analyzed (Laboklin).
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